Trastuzumab biosimilar (Anke Biotech)

曲妥珠单抗生物类似药（安科生物）

Report date: 2023/11/01 16:50:50

Base Information

Drug NameTrastuzumab biosimilar (Anke Biotech)
Drug Alias Name曲妥珠单抗生物仿制药（安科生物）
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsBreast Neoplasms
Approved Indications in ChinaBreast Neoplasms
Original Approved Country/TerritoryMainland China
Original Approved Date2023/10/27
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAnhui Anke Biotechnology (Group) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAnhui Anke Biotechnology (Group) Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeL01XC03
Related LinksN/A